Novo Nordisk vs Pfizer
Novo Nordisk (NVO), health care, and Pfizer (PFE), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Novo Nordisk is worth $179B on the stock market and Pfizer $162.8B: Novo Nordisk is valued at 10% more. Novo Nordisk trades at 10.3 times earnings and Pfizer at 40.8. Over the past year Novo Nordisk's share price has moved -12.5% and Pfizer's +13.4%.
Key facts
- Novo Nordisk market value
- $179B
- Pfizer market value
- $162.8B
- Novo Nordisk P/E
- 10.3
- Pfizer P/E
- 40.8
- Novo Nordisk revenue
- $45.9BFY to 2025-12-31
- Pfizer revenue
- $62.6BFY to 2025-12-31
- Superinvestors holding both
- 2
Market values as of .
| Measure | Novo Nordisk | Pfizer |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $179Bhigher | $162.8Blower |
| Revenue | $45.9Blower | $62.6Bhigher |
| Earnings | $15.2Bhigher | $7.8Blower |
| Employees | 68,794lower | 75,000higher |
| Total assets | $80.6Blower | $208.2Bhigher |
| Valuation | ||
| P/E | 10.3lower | 40.8higher |
| P/S | 3.9higher | 2.6lower |
| P/B | — | 1.8 |
| Dividend yield | — | 7.45% |
| Profitability | ||
| Operating margin | 41.3% | — |
| Balance sheet | ||
| Net assets | $28.8Blower | $86.5Bhigher |
| Total liabilities | $51.8Blower | $121.4Bhigher |
| Total debt | $19.4Blower | $64.8Bhigher |
| Cash on hand | $3.9Bhigher | $1.1Blower |
| Price change | ||
| Today | -2.38%lower | -1.06%higher |
| 1 year | -12.5%lower | +13.4%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (2)
- Charles Brandes (founder)0.2% / 1.5%
- Ken Fisher0.1% / 0.9%
Novo Nordisk only (6)
Pfizer only (9)
- Thomas Kahn1.9%
- Mark Boyar1.6%
- Prem Watsa1.5%
- Josef Lakonishok1.0%
- Richard Pzena0.5%
- Bruce Berkowitz0.4%
- Jeremy Grantham (co-founder)0.1%
- Murray Stahl<0.1%
- Mairs & Power team<0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Novo Nordisk / Pfizer). Who owns NVO · Who owns PFE
More on Novo Nordisk
Further comparisons
Novo Nordisk against its closest peers
Pfizer against its closest peers
Learn
Questions and answers
Which is bigger, Novo Nordisk or Pfizer?
By market value, Novo Nordisk is the larger: $179B against $162.8B for Pfizer. By revenue in its latest fiscal year, Pfizer is the larger: $62.6B against $45.9B for Novo Nordisk.
Which has the higher P/E ratio?
Pfizer: 40.8, against 10.3 for Novo Nordisk. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has more debt?
Pfizer: $64.8B, against $19.4B for Novo Nordisk. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Novo Nordisk and Pfizer?
In their latest 13F filings, Charles Brandes (founder) and Ken Fisher hold both.
Cite this page
Funkfolio, “Novo Nordisk vs Pfizer”, data as of 17 November 2026. https://funkfolio.com/compare/nvo-vs-pfe
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.